Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: ZFP36L2

Summary for ZFP36L2

Gene information	Gene symbol	ZFP36L2
	Ensembl ID	ENSG00000152518
	Entrez ID	678
	Gene name	ZFP36 ring finger protein like 2
	Synonyms	BRF2\|ERF2\|RNF162C\|TIS11D
	Gene type	protein_coding
	UniProtAcc	P47974

Top

Dataset with differentially expressed gene: ZFP36L2

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	0.379113	0.00e+00
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	-0.418331	3.47e-09
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.364182	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.565948	2.03e-11
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Progenitors	0.752723	6.85e-05
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.646459	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	0.341668	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	1.06299	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.91066	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.626978	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	1.10094	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	1.15668	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	1.01493	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	pDCs	1.43839	2.61e-23
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	-0.288436	3.65e-32
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	-0.955523	8.72e-39
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	-0.504705	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.323505	2.05e-11
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.64301	0.00e+00
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-1.36884	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	pDCs	-0.701898	2.11e-03
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.658076	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.254483	5.03e-23
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	0.512312	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	0.399955	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	0.518969	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	0.480436	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	0.589341	5.73e-20
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.563829	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD4+ T cells	-0.313622	1.04e-19
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	-1.33052	1.53e-23
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.846078	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	post	B cells	0.449563	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	pre	NK cells	0.27587	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	pre	CD4+ T cells	0.276113	0.00e+00
GSE150930	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Mucosa-assisted lymphoid tissue (MALT) lymphoma	Immunotherapy	rituximab + cyclophosphamide + fludarabine	NA	Malignant cells	-0.39637	1.16e-15
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	1.29122	3.58e-40
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD4+ T cells	-0.373225	1.83e-38
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD8+ T cells	-0.402127	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.87805	2.19e-29
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	1.39008	7.68e-12
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Plasma cells	0.538473	3.81e-05
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.465322	2.89e-10
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-0.42847	1.46e-06
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	pDCs	1.06809	2.09e-03
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Mono/Macro	0.284487	1.07e-13
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	1.58597	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	-0.307961	3.41e-18
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	-0.822778	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	0.765531	4.83e-18
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD8+ T cells	-0.654908	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	0.445761	7.92e-19
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	-0.773764	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	-0.472618	4.56e-07
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	1.03148	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	-0.387162	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	1.05013	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	Malignant cells	-0.317443	7.03e-13
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD8+ T cells	-0.47145	1.61e-21
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD4+ T cells	-0.71045	7.60e-19
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD8+ T cells	-0.784484	1.30e-34
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	Malignant cells	-0.457409	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	NK cells	-0.698521	4.42e-05
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	Malignant cells	0.264555	0.00e+00
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	CD8+ T cells	0.565805	2.83e-05
GSE104987	MCF7 cell line	Cell line	Breast cancer	ER+ breast cancer	Targeted therapy	KDM5-C70	NA	Malignant cells	-0.725233	0.00e+00
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-0.428602	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	0.31639	5.32e-40
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	B cells	0.538703	1.08e-26
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	-0.342609	0.00e+00

Top

Expression of ZFP36L2 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to ZFP36L2

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating ZFP36L2

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
ZFP36L2	hsa-miR-4262	99.5802	NM_006887
ZFP36L2	hsa-miR-3910	99.4661	NM_006887
ZFP36L2	hsa-miR-181c-5p	99.3891	NM_006887
ZFP36L2	hsa-miR-181d-5p	99.3891	NM_006887
ZFP36L2	hsa-miR-181a-5p	99.3891	NM_006887
ZFP36L2	hsa-miR-181b-5p	99.3891	NM_006887
ZFP36L2	hsa-miR-144-3p	98.7346	NM_006887
ZFP36L2	hsa-miR-101-3p	98.5756	NM_006887
ZFP36L2	hsa-miR-4291	96.935	NM_006887
ZFP36L2	hsa-miR-6739-3p	95.8663	NM_006887
ZFP36L2	hsa-miR-6505-5p	95.7726	NM_006887
ZFP36L2	hsa-miR-12122	95.2531	NM_006887
ZFP36L2	hsa-miR-4796-3p	94.4688	NM_006887
ZFP36L2	hsa-miR-137-3p	94.1181	NM_006887
ZFP36L2	hsa-miR-449c-3p	94.062	NM_006887
ZFP36L2	hsa-miR-513b-5p	93.6801	NM_006887
ZFP36L2	hsa-miR-1-3p	93.5665	NM_006887
ZFP36L2	hsa-miR-206	93.5665	NM_006887
ZFP36L2	hsa-miR-9983-3p	92.7577	NM_006887
ZFP36L2	hsa-miR-4704-3p	91.8836	NM_006887
ZFP36L2	hsa-miR-129-5p	91.4091	NM_006887
ZFP36L2	hsa-miR-3686	91.4086	NM_006887
ZFP36L2	hsa-miR-373-5p	91.2803	NM_006887
ZFP36L2	hsa-miR-371b-5p	91.2803	NM_006887
ZFP36L2	hsa-miR-616-5p	91.2803	NM_006887
ZFP36L2	hsa-miR-375-3p	91.2433	NM_006887
ZFP36L2	hsa-miR-12136	91.0824	NM_006887
ZFP36L2	hsa-miR-4743-3p	91.0367	NM_006887
ZFP36L2	hsa-miR-5002-5p	91.0333	NM_006887
ZFP36L2	hsa-miR-613	90.8403	NM_006887
ZFP36L2	hsa-miR-302c-5p	89.738	NM_006887
ZFP36L2	hsa-miR-936	88.7873	NM_006887
ZFP36L2	hsa-miR-335-3p	88.193	NM_006887
ZFP36L2	hsa-miR-548t-5p	88.0663	NM_006887
ZFP36L2	hsa-miR-548az-5p	88.0663	NM_006887
ZFP36L2	hsa-miR-525-5p	87.4298	NM_006887
ZFP36L2	hsa-miR-520a-5p	87.4298	NM_006887
ZFP36L2	hsa-miR-4652-3p	87.1106	NM_006887
ZFP36L2	hsa-miR-138-5p	86.6986	NM_006887
ZFP36L2	hsa-miR-198	86.5125	NM_006887
ZFP36L2	hsa-miR-4803	86.2425	NM_006887
ZFP36L2	hsa-miR-4693-5p	86.179	NM_006887
ZFP36L2	hsa-miR-1279	86.1129	NM_006887
ZFP36L2	hsa-miR-5003-3p	86.0644	NM_006887
ZFP36L2	hsa-miR-4263	85.3446	NM_006887
ZFP36L2	hsa-miR-1277-5p	84.5879	NM_006887
ZFP36L2	hsa-miR-421	84.5539	NM_006887
ZFP36L2	hsa-miR-4282	84.3813	NM_006887
ZFP36L2	hsa-miR-4665-5p	84.3791	NM_006887
ZFP36L2	hsa-miR-1275	84.3791	NM_006887

Page: 1 2

Top

Motifs and transcription factors (TFs) regulating ZFP36L2

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
ZFP36L2	transfac_pro__M06534	ZNF563 (directAnnotation).
ZFP36L2	metacluster_111.6	GMEB1; GMEB2 (directAnnotation).
ZFP36L2	metacluster_7.13	ZFX (directAnnotation).
ZFP36L2	metacluster_151.2	ZNF23 (directAnnotation).
ZFP36L2	metacluster_170.2	KLF1; KLF10; KLF10; KLF11; KLF11; KLF11; KLF12; KLF12; KLF14; KLF15; KLF17; KLF2; KLF5; KLF7; KLF7; KLF8; MAZ; MAZ; PATZ1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP4; SP4; SP5; SP6; SP7; SP8; SP9; ZNF281 (directAnnotation). E2F1; E2F4; KLF10; KLF13; KLF14; KLF17; KLF2; KLF7; SP1; SP1; SP3; SP4; SP5; SP6; SP7 (inferredBy_Orthology).
ZFP36L2	metacluster_155.23	BCL11B; ZNF711; ZNF711 (directAnnotation). ZFY (inferredBy_Orthology).
ZFP36L2	kznf__ZNF783_Imbeault2017_OM_MEME	ZNF783 (directAnnotation).
ZFP36L2	metacluster_144.3	ZNF704; ZNF704 (directAnnotation).
ZFP36L2	metacluster_135.10	MBD2; MBD2; MECP2; MECP2 (directAnnotation).
ZFP36L2	hdpi__NFIX	NFIX (directAnnotation).
ZFP36L2	transfac_pro__M03813	POU3F3 (directAnnotation).
ZFP36L2	hocomoco__MNX1_HUMAN.H11MO.0.D	MNX1 (directAnnotation).
ZFP36L2	hdpi__ZNF193	ZSCAN9 (directAnnotation).
ZFP36L2	hdpi__FOXM1	FOXM1 (directAnnotation).
ZFP36L2	transfac_pro__M06074	ZNF732 (directAnnotation).
ZFP36L2	transfac_pro__M01219	SP1 (directAnnotation). SP3 (inferredBy_Orthology).
ZFP36L2	transfac_pro__M07397	ZNF148 (directAnnotation).
ZFP36L2	metacluster_15.2	E2F1; E2F1; E2F1; E2F1; E2F1; E2F3; E2F4; E2F4; E2F4; E2F6; E2F6; E2F6; E2F6; E2F6; E2F6; E2F6; E2F7; TFDP1; TFDP2; ZNF566; ZNF566; ZNF574 (directAnnotation). E2F3; E2F3; E2F4 (inferredBy_Orthology).
ZFP36L2	metacluster_3.11	SP1; SP1; SP2; SP3; SP3; SP4 (directAnnotation).
ZFP36L2	homer__GGGGGGGG_Maz	MAZ (directAnnotation).
ZFP36L2	transfac_pro__M01175	ZBTB7B (directAnnotation).
ZFP36L2	metacluster_3.7	SP1; SP1; SP1; SP1; SP1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP3; SP3; SP3; SP4; SP4; SP4; SP4; SP4; SP4; SP5 (directAnnotation).
ZFP36L2	metacluster_15.1	E2F4; E2F4; E2F4; E2F4; E2F7; ZFP69B (directAnnotation). E2F4 (inferredBy_Orthology).
ZFP36L2	transfac_pro__M01303	SP1 (directAnnotation).
ZFP36L2	swissregulon__hs__CHD1	CHD1 (directAnnotation).
ZFP36L2	transfac_pro__M02089	E2F3 (directAnnotation).
ZFP36L2	metacluster_3.14	WT1; WT1 (directAnnotation).
ZFP36L2	hocomoco__EGR4_HUMAN.H11MO.0.D	EGR4 (directAnnotation).
ZFP36L2	cisbp__M07938	E2F1 (directAnnotation).
ZFP36L2	homer__GGCGGGAARN_E2F6	E2F6 (directAnnotation).
ZFP36L2	transfac_pro__M07436	WT1 (directAnnotation).
ZFP36L2	transfac_pro__M02281	SP1 (directAnnotation).
ZFP36L2	kznf__ZNF730_Imbeault2017_RP_RCADE	ZNF730 (directAnnotation).
ZFP36L2	transfac_pro__M07461	KLF1; KLF10; KLF11; KLF12; KLF13; KLF15; KLF16; KLF17; KLF2; KLF3; KLF4; KLF5; KLF6; KLF7; KLF8; KLF9 (directAnnotation).
ZFP36L2	metacluster_135.8	ZNF516; ZNF536 (inferredBy_Orthology).
ZFP36L2	transfac_pro__M01252	E2F6 (directAnnotation).
ZFP36L2	tfdimers__MD00488	ELF1; HDX (directAnnotation).
ZFP36L2	kznf__ZNF384_Schmitges2016_RCADE	ZNF384 (directAnnotation).
ZFP36L2	transfac_pro__M07431	SOX11 (directAnnotation).
ZFP36L2	transfac_pro__M05507	IKZF3 (directAnnotation).
ZFP36L2	metacluster_167.5	EHF; ELF5; NFATC3; SPI1; SPI1; SPI1; SPI1; SPI1; SPI1; SPI1; SPI1; SPI1; SPI1; SPI1; SPIB; SPIB; SPIB; SPIB; SPIB; SPIB; SPIB; SPIB; SPIB; SPIB; SPIC; SPIC; STAT5A (directAnnotation). ETS1; SPI1; SPI1; SPI1; SPI1; SPI1; SPI1; SPIB; SPIC (inferredBy_Orthology).
ZFP36L2	transfac_pro__M05916	ZNF407 (directAnnotation).
ZFP36L2	tfdimers__MD00204	GABPA; NKX2-1 (directAnnotation).
ZFP36L2	transfac_pro__M05977	ZNF257 (directAnnotation).
ZFP36L2	transfac_public__M00415	ZEB1 (directAnnotation).
ZFP36L2	metacluster_130.1	ZNF713; ZNF713 (directAnnotation). HSF1; HSF2; HSF4; HSF5; HSFX1; HSFX2; HSFX3; HSFX4; HSFY1; HSFY2 (inferredBy_Orthology).
ZFP36L2	tfdimers__MD00259	HOXA13; MAFA (directAnnotation).
ZFP36L2	transfac_pro__M06794	ZNF107 (directAnnotation).
ZFP36L2	metacluster_41.38	SOX21 (inferredBy_Orthology).
ZFP36L2	tfdimers__MD00044	ELF1; ELF2; ELF4; ELK1; ELK3; ELK4; ERG; ETS1; ETS2; ETV4; ETV6; ETV7; FLI1; GABPA; GABPB1; SIRT6; SPI1; SPIB (directAnnotation).

Page: 1 2 3 4 5 6 7 8 9

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."